This article was originally published in The Tan Sheet
IVAX Pharmaceuticals is issuing a voluntary recall of Goldline Extra Strength Genapap and Extra Strength Genebs (both 500 mg acetaminophen) in caplet and tablet form, FDA announces May 2. The Miami, Fla.-based firm is recalling 30 lots due to a labeling error, according to the agency. The product labels should indicate that usage is not to exceed eight tablets/caplets in a 24-hour period; however, the erroneous label indicates not to exceed 12 tablets/caplets in a 24-hour period. If more than eight tablets/caplets are ingested in a 24-hour period, patients may face an increased risk of acetaminophen toxicity to the liver, FDA notes. Consumers are urged to "cease usage and return the product to the location of purchase." Retailers and wholesalers are encouraged to return all unsold lots to IVAX...
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."